• Earlier in March 2026, Trevi Therapeutics announced it had completed an End-of-Phase 2 meeting with the FDA and secured alignment to run two global, randomized Phase 3 trials of nalbuphine ER (Haduvio) for IPF-related chronic cough, with both studies using 54 mg twice-daily dosing and cough-frequency reduction as the primary endpoint.
• An interesting aspect is that Trevi plans to run two pivotal Phase 3 trials in parallel, even though the FDA indicated one could be sufficient, potentially providing a broader evidence base for any future New Drug Application in a high-need respiratory indication.
• We will now examine how Trevi’s decision to pursue two parallel global Phase 3 trials could influence the company’s broader investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

What Is Trevi Therapeutics' Investment Narrative?

To own Trevi today, you really have to believe in Haduvio as a differentiated, late‑stage asset in a high‑need niche, and in management’s ability to turn convincing clinical data into an approved, commercial product. The recent FDA End‑of‑Phase 2 alignment and decision to run two global Phase 3 trials in parallel looks like a meaningful shift in the near‑term story: the main catalyst now becomes successful execution and readouts from these studies, rather than incremental Phase 2 updates. At the same time, the plan likely increases Trevi’s cash needs and execution risk, which matters for a company with no revenue, ongoing losses and a history of shareholder dilution. The strong share price run over the past year, despite recent pullbacks, also heightens sensitivity to any trial or financing setbacks linked to this expanded Phase 3 program.

However, one funding‑related risk tied to the larger Phase 3 plan is easy to miss. Our valuation report here indicates Trevi Therapeutics may be overvalued.

Exploring Other Perspectives

Two Simply Wall St Community fair values, from about US$21.55 to US$35, show how far apart individual views sit. Against that backdrop, the expanded Phase 3 program concentrates attention on clinical execution and future financing needs, which could be just as important for Trevi’s trajectory as any valuation model.

Explore 2 other fair value estimates on Trevi Therapeutics - why the stock might be worth just $21.55!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Trevi Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free Trevi Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Trevi Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.